JP2006282581A - Tryptophan intermediate metabolite having efficacy on inhibition of chlamydia bacterium - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a material for effectively inhibiting the infection and proliferation of chlamydia bacteria; and to provide a method for utilizing the material. <P>SOLUTION: The medicinal composition or the food composition contains a tryptophan intermediate metabolite which inhibits the infection or the proliferation of the chlamydia bacteria as an active ingredient. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a pharmaceutical composition and a food composition effective for the prevention and treatment of bacterial infections. Specifically, the present invention is characterized by suppressing infection or growth of Chlamydia bacteria, and contains tryptophan metabolites as an active ingredient. The present invention relates to a pharmaceutical composition and a food composition.

  Chlamydiaceae is an obligate intracellular parasitic bacterium that can grow only in cells of eukaryotes such as humans. Chlamydia trachomatis (Chlamydia trachomatis) is mainly a disease. Infecting the genital organs and becoming the first cause of sexually transmitted diseases in Japan, it has become widely known. Chlamydia pneumoniae (Chlamydophila pneumoniae) mainly infects inflammatory sites in the lungs and arteries and is a causative agent of colds, and at the same time, has been pointed out to be associated with arteriosclerosis and ischemic heart disease. Chlamydia pitaci is known to infect the respiratory tract mainly from the trachea to the lungs, causing pneumonia as a causative bacterium of parrot disease, and Chlamydophila felis (cat chlamydia) Infection has also been reported with examples of human infectious diseases such as infecting the mucous membrane of human eyes and causing conjunctivitis, and countermeasures against chlamydia as infection-causing bacteria are urgently needed.

  There are two major problems in dealing with Chlamydia infection. The first is the mildness of symptoms appearing on the surface. Infections caused by the sexually transmitted disease Chlamydia (obvious sexually transmitted infection) and infections caused by Chlamydia pneumonia are characterized by symptoms that usually resemble those of a common cold, and severe symptoms that may require treatment. There is a problem that infection and symptoms are secretly advanced.

  The second problem is that when symptoms that require treatment appear, the antibiotics used in the treatment are superficially effective and are understood as if the disease was perceived. is there. Chlamydia infections are concealed by mild superficial symptoms, and as a result of long-term latent / persistent infections, sexually transmitted diseases chlamydia cause pelvic infections and infertility, and pneumonia chlamydia develops into lung cancer and arteriosclerosis There is a danger. As a strategy for Chlamydia infection, superficial treatment only when it worsens, such as treatment with antibiotics or antibodies, is insufficient, and it is necessary to take prevention and prevent persistent infection.

Currently, development of vaccines against sexually transmitted diseases, Chlamydia pneumoniae and Chlamydia pneumoniae is also underway worldwide. Vaccines against animal chlamydia have been developed and are already on the market. Unfortunately, however, no vaccine has been developed that is effective against chlamydial infections. Moreover, in the vaccine using the whole microbial cell, the possibility that the heat shock protein contained in the microbial cell worsens the inflammatory reaction, arteriosclerosis, etc. by Chlamydia infection is reported. In other words, the strategy against Chlamydia infection includes the development of safer and more effective vaccines, and the establishment of treatment methods and constitutional improvements that can eliminate “potentially present Chlamydia” based on the characteristics of Chlamydia infection. It is essential.
Patent No. 3402304 Method for producing cat chlamydia vaccine Patent application title: Chlamydia Infectious Disease Treatment Agent JP-A-2001-288114 Autoimmune disease therapeutic agent Patent No. 3402304 Method for producing cat chlamydia vaccine Rottenberg ME G-RA et al. (2002) Curr. Opin. Immunol. 14: 444-451 Belland RJ et al. (2003) Proc. Natl. Acad. Sci. U. S. A. 100: 15971-15976 Carlson LL. et al. (1989) Endocrinology 25: Jun. 70 Chan AS et al. (2002) Cell Signal. 14: 249-257 Shirai M HH et al. (2000) Nucleic Acids Res. 28: Apr. 11 Matsushima H et al. (2002) J. Org. Vet. Med. Sci. 64: 215-219

  In view of the above-mentioned present situation, the present invention aims to provide substances that effectively suppress the infection or proliferation of Chlamydia bacteria and methods for using these substances.

  The present inventors are proceeding with elucidation of recent pathogenicity of Chlamydia by genome analysis and information science comparative analysis. From the analysis, it has been clarified that in Chlamydia bacteria, there is a large “fluctuation” including the presence or absence of the tryptophan synthase gene group (FIG. 5). Focusing on this point, it was found that tryptophan metabolism intermediates, particularly melatonin and serotonin, have an effect of inhibiting chlamydia infection and proliferation while using tryptophan metabolism inhibitors in chlamydia infection experiments and the like. Melatonin and serotonin are known as neurotransmitters, but there are no similar reports on the effects of inhibiting chlamydial infection and proliferation in the well-known medical and biology-related literature. It was considered to be an action.

  That is, the present invention provides a pharmaceutical composition or a food composition characterized by suppressing infection or growth of Chlamydia bacteria and containing a tryptophan metabolic intermediate product as an active ingredient.

  The first aspect of the present invention provides a composition comprising a tryptophan metabolic intermediate product as an active ingredient, which suppresses infection or growth of Chlamydia bacteria.

  According to a second aspect of the present invention, there is provided a pharmaceutical composition comprising a tryptophan metabolic intermediate product as an active ingredient, characterized by suppressing infection or growth of Chlamydia bacteria, wherein the tryptophan metabolic intermediate product is 5-hydroxy There is provided a pharmaceutical composition characterized in that it is selected from at least one of tryptophan, melatonin, serotonin and pharmacologically acceptable salts, esters or derivatives thereof.

  A third aspect of the present invention provides a pharmaceutical composition, wherein the tryptophan metabolic intermediate product in the second aspect is selected from at least one of 5-hydroxytryptophan, melatonin, and serotonin.

  According to a fourth aspect of the present invention, there is provided a pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, wherein the tryptophan metabolism intermediate product is an active ingredient, and the tryptophan metabolism intermediate product is 5- A pharmaceutical composition characterized in that it is selected from at least one of hydroxytryptophan, serotonin, and melatonin, and the effective concentration of the suppression is in the range of 2 to 10 times the concentration in the body. I will provide a.

  According to a fifth aspect of the present invention, there is provided a pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, wherein the tryptophan metabolism intermediate product is an active ingredient, and the tryptophan metabolism intermediate product is 5- Provided is a pharmaceutical composition characterized in that it is selected from at least one of hydroxytryptophan, serotonin, and melatonin, and the effective concentration of the inhibition is in the range of 5 μM to 500 μM.

  According to a sixth aspect of the present invention, there is provided a pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, wherein the tryptophan metabolism intermediate product is an active ingredient, and the tryptophan metabolism intermediate product is 5- It is selected from at least one of hydroxytryptophan, serotonin, and melatonin, and the effective concentration of the inhibition is within the range of 50 μM to 500 μM for 5-hydroxytryptophan, within the range of 50 μM to 100 μM for serotonin, melatonin Provides a pharmaceutical composition characterized by being in the range of 5 μM to 500 μM.

  According to a seventh aspect of the present invention, there is provided a pharmaceutical composition characterized by suppressing infection or proliferation of Chlamydia spp., Comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the Chlamydia spp. There is provided a pharmaceutical composition characterized by being at least one of Mathis, Chlamydia pneumoniae, Chlamydia sitashi, Chlamydia ferris.

  According to an eighth aspect of the present invention, there is provided a pharmaceutical composition characterized by suppressing infection or proliferation of Chlamydia spp., Comprising a tryptophan metabolite as an active ingredient, wherein the Chlamydia spp. The pharmaceutical composition according to any one of the second to sixth aspects, characterized in that it is at least one of Mathis, Chlamydia pneumoniae, Chlamydia sitashi, Chlamydia ferris To do.

  According to a ninth aspect of the present invention, there is provided a pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the drug is an oral drug, an applied drug, Provided is a pharmaceutical composition characterized by being selected from any one of eye drops and injections.

  A tenth aspect of the present invention is a pharmaceutical composition characterized by suppressing infection or proliferation of Chlamydia spp., Comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the drug is an oral drug, an applied drug, The pharmaceutical composition according to any one of the second to eighth aspects, characterized in that it is selected from any one of eye drops and injections.

  An eleventh aspect of the present invention provides a food composition characterized by suppressing infection or proliferation of Chlamydia bacteria, and comprising a tryptophan metabolic intermediate product as an active ingredient.

  A twelfth aspect of the present invention is a food composition characterized by suppressing infection or proliferation of Chlamydia bacteria, wherein the tryptophan metabolism intermediate product is an active ingredient, and the tryptophan metabolism intermediate product is 5- Provided is a food composition characterized in that it is selected from at least one of hydroxytryptophan, serotonin, melatonin and their pharmacologically acceptable salts, esters or derivatives.

  A thirteenth aspect of the present invention is a food composition characterized by suppressing infection or growth of Chlamydia bacteria, wherein the tryptophan metabolic intermediate product is 5- Provided is a food composition characterized by being selected from at least one of hydroxytryptophan, serotonin, and melatonin.

  A fourteenth aspect of the present invention is a food composition characterized by suppressing infection or proliferation of Chlamydia spp., Wherein the tryptophan metabolic intermediate product is an active ingredient, wherein the tryptophan metabolic intermediate product is 5- Provided is a food composition characterized in that it is selected from at least one of hydroxytryptophan, serotonin, and melatonin, and the food is one kind of candy, gum, and soft drink.

  According to a fifteenth aspect of the present invention, there is provided a food comprising the food composition according to any one of the eleventh to fourteenth aspects, which suppresses infection or proliferation of Chlamydia bacteria. .

  By using the pharmaceutical composition described in the present invention, it is possible to produce a drug that is effective against Chlamydia spp. That is a causative bacterium of chronic infections and that is safe for the human body.

  Further, by using the food composition described in the present invention, it is possible to produce a functional food that can prevent infection with Chlamydia bacteria relatively easily and safely and inexpensively. As countermeasures against Chlamydia bacteria that cause chronic infections, in addition to the therapeutic effects of drugs, the preventive effects of foods and the like can be fully utilized.

  The best mode for carrying out the present invention will be described below. The first aspect of the present invention provides a composition comprising a tryptophan metabolic intermediate product as an active ingredient, which suppresses infection or growth of Chlamydia bacteria. As described above, although these substances are known, the “effect on Chlamydia bacteria” has not been known so far, and it is disclosed that these substances are used as a composition of a drug or food.

  In the second to sixth aspects of the present invention, there is disclosed a pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria and containing a tryptophan metabolic intermediate product as an active ingredient. The tryptophan metabolic intermediate product is selected from at least one of 5-hydroxytryptophan, serotonin, melatonin and pharmacologically acceptable salts, esters or derivatives thereof, preferably 5-hydroxytryptophan, serotonin In order to obtain the suppression effect, the concentration of 5-hydroxytryptophan, serotonin, and melatonin is preferably 2 to 10 times the concentration in the body. The pharmaceutical composition is within the range, or the concentration of 5-hydroxytryptophan, serotonin, melatonin is in the range of 5 μM to 500 μM, more specifically in the range of 50 μM to 500 μM for 5-hydroxytryptophan, 50 μM for serotonin In the range of 100 μM and melatonin in the range of 5 μM to 500 μM. As described in the examples below, the present inventors have revealed that three substances of 5-hydroxytryptophan, serotonin, and melatonin have an inhibitory effect on chlamydia infection, so a pharmaceutical composition using this property is presented. Is done.

  Fig. 1 shows the tryptophan metabolic pathway in human cells, showing the effect on Chlamydia bacteria, and in addition to melatonin and serotonin synthesized in the human body, these are chemically modified substances that have an adverse effect on human cells. Substances that do not exert can also be used as pharmaceutical compositions. Both melatonin and serotonin are synthesized from tryptophan in the human body, but the above effects on Chlamydia spp. Cannot be expected at the concentration in the body. For example, it shows effects on human cells infected with Chlamydia spp. In the range of 2 to 10 times the concentration in the body is desirable. This concentration has a sufficient effect on Chlamydia bacteria and does not adversely affect human cells.

  In the seventh and eighth aspects of the present invention, it is characterized in that the infection or growth of Chlamydia spp. Is suppressed, and is a pharmaceutical composition comprising a tryptophan metabolite as an active ingredient, wherein the Chlamydia spp. Provided is a pharmaceutical composition characterized by being at least one of Chlamydia trachomatis, Chlamydia pneumoniae, Chlamydia sitasi, Chlamydia ferris. These chlamydia are common in that they can infect human cells and cause disease, but the main parasites and pathological conditions differ depending on the species.For example, Chlamydia trachomatis affects the reproductive organs, Chlamydia Pneumoniae is known to infect inflammatory sites in the lungs and arteries, chlamydial weasel to airways from the trachea to lungs, and chlamydia ferris to the eye mucosa. It is necessary to administer the drug in an appropriate form for these individual infections, and by limiting the target bacteria, it is possible to develop a drug that can be expected to have a higher effect.

  According to the ninth and tenth aspects of the present invention, there is provided a pharmaceutical composition characterized by suppressing infection or proliferation of Chlamydia bacteria, wherein the pharmaceutical composition comprises a tryptophan metabolic intermediate product as an active ingredient, wherein the drug is an oral drug. A pharmaceutical composition characterized by being selected from any one of a coating agent, an eye drop, and an injection. As described above, Chlamydia spp. Have different main infection sites and symptoms for each species, and it is desirable that the mode of the drug corresponding to the infection site be adapted to the symptoms. For example, for Chlamydia trachomatis infection, drugs applied to the affected area and oral drugs; for Chlamydia pneumoniae infection and Chlamydia sitasi infection, application drugs or oral drugs or injections to the throat mucosa; Chlamydia ferris infection In contrast, administration forms of drugs according to individual infections such as eye drops are preferable. It is also within the scope of the present invention to create a drug having a higher effect by changing the concentration of the active ingredient or changing the combination of the drug in the individual forms of the bacteria. It is.

  In the eleventh to fifteenth aspects of the present invention, there is provided a food composition characterized by suppressing infection or proliferation of Chlamydia, and comprising a tryptophan metabolic intermediate product as an active ingredient. As described above, tryptophan metabolites are extremely safe substances synthesized in the human body, and as described in the examples below, the inhibitory effect of tryptophan metabolites on chlamydia is so-called “bactericidal” against Chlamydia. In view of the chronic infection situation of Chlamydia bacteria, the present invention is not an effect, but is a “preventive” effect that gently acts on host cells and makes it difficult to infect Chlamydia. It can be used not only as a pharmaceutical composition but also as a food composition. The tryptophan metabolic intermediate of the present invention is not particularly limited as long as it has an effect of suppressing infection or proliferation of Chlamydia bacteria, but preferably 5-hydroxytryptophan, serotonin, melatonin and these drugs It is selected from at least one of salts or esters or derivatives that are physically acceptable, and more preferably selected from at least one of 5-hydroxytryptophan, serotonin, and melatonin. The form of the food in the embodiment of the present invention is not particularly limited as long as it retains the effect on the Chlamydia spp., But preferably suppresses infection and proliferation of the Chlamydia spp. It may be provided in the form of a throat candy for the purpose, provided in the form of chewing gum for the same purpose, or provided as one ingredient of a soft drink. In any case, any food that has a tryptophan metabolite as an active ingredient and exhibits a preventive effect against Chlamydia infection is considered to be within the scope of the present disclosure.

  The meanings of the abbreviations used in this example are as follows. IFN-γ; interferon-γ, IFU; inclusion formation unit, FCS; physical calf serum, MOI; notification of infection, EB; elementary body, identi- ede3, ID3; : 5'-cyclic monophosphate.

HEp-2 cells (ATCC Ccl-23) were used as host cells for chlamydia infection experiments at 37 ° C. in HEp-2 culture medium (Dulbecco's modified Eagle medium, 10% heat-inactivated FCS, 50 μg / ml gentamicin). Culturing was performed under the condition of a carbon concentration of 5%. Examples of Chlamydia strains include C.I. pneumoniae J138 strain (Pneumonia chlamydia), C.I. felis Fe / C-56 strain (cat chlamydia), C.I. trachomatis sever D strain (sexually transmitted disease Chlamydia) was used. In the experiment, Escherichia coli, Staphylococcus aureus, Bacillus subtilis E192, Streptococcus pneumoniae, Pseudomonas aeruginosa PAO1, Helicobacter CP34 were used as other bacteria. The procedure of Chlamydia infection experiment is as follows. 2 × 10 4 (in 0.1 ml) HEp-2 cells are dispensed into a 96-well plate and cultured for 24 hours. Chlamydia EB is added here so that it may become 0.2 MOI, and it centrifuges at 22 degreeC and 700 xg for 60 minutes, and sets it for 30 minutes. These cells are transferred to a post-infusion medium (Dulbecco's modified Eagle medium, 5% heat-inactivated FCS, 50 μg / ml gentamicin, 1 μg / ml cycloheximide), and cultured at CO _{2 for} 5 hours at 36 ° C. for 5 hours. A schedule of drug treatment in the experiment is shown in FIG. Chlamydia infection rate was measured by the following method. Infected host cells were fixed with methanol for 30 minutes, FITC-labeled Chlamydia bacteria-specific antibody was reacted for 1 hour (37 ° C.), and then the host cell nucleus was stained with DAPI (0.1 μg / ml) for 10 minutes. Host cells and Chlamydia inclusion bodies (diameter 1.0 μm or more) were counted using a fluorescence microscope. The infection rate was calculated from the average value of three independent experiments. The effect of melatonin on bacteria other than the above chlamydia was examined by adding melatonin or gentamicin to each medium, culturing at 37 ° C. for 8 hours (24 hours for H. pylori), and then measuring 600 nm OD.

  We tested the effects of tryptophan metabolites in in vitro infection experiments with Chlamydia pneumonia J138 using human HEp-2 cells. 5-Hydroxytryptophan, serotonin and melatonin significantly inhibited the growth of chlamydia compared to the control. (FIG. 1). In order to compare with the known chlamydial growth inhibitory effect of IFN-γ (which causes tryptophan deficiency, the effect is counteracted by the addition of tryptophan), when tryptophan addition experiment was conducted, IFN-γ In contrast, addition of tryptophan did not counteract the growth inhibitory effect of chlamydia (FIG. 2), and it was not observed that chlamydial infection led to persistent infection. Furthermore, it was found that melatonin and serotonin have an inhibitory effect on feline chlamydia with almost complete set of tryptophan synthesis gene, partly sexually transmitted disease chlamydia and completely lacking pneumoniae chlamydia. (Figure 3). On the other hand, no inhibitory effect was observed on tryptophan metabolites even when administered at high concentrations against 10 types of human resident bacteria.

  In order to clarify the effects of melatonin and serotonin on chlamydia infection, this cell is pretreated with these substances to determine whether this effect is on chlamydia or on host cells, and subsequent infection The effect on As a result, when host cells were pretreated with melatonin or serotonin, an infection inhibitory effect was observed, but pretreatment on chlamydia cells had little effect on infection (FIG. 4). This result indicates that the effects of melatonin and serotonin are on host cells. Regarding melatonin and serotonin, it is known that there are receptors involved in uptake and signal transduction in various human tissue cells, and many of these receptors are receptors that bind G protein. is there. Therefore, pertussis toxin, which is an inhibitor of G protein, was used to examine the influence of melatonin and serotonin on the inhibitory effect on chlamydia infection. As a result, for serotonin, the pertussis toxin treatment counteracted the infection inhibitory effect, while melatonin did not affect the infection inhibition with melatonin (FIG. 4). This indicates that the host G protein is involved in the chlamydia inhibitory effect of serotonin but not the melatonin effect.

Figure 2 shows the effect of tryptophan and its metabolic intermediates on chlamydia infection in in vitro conditions. A: A schematic diagram of a tryptophan metabolic pathway comprising a kynurenine pathway and a serotonin pathway is shown. B: Represents time settings for chlamydia infection and drug treatment under in vitro conditions in this study. In most experiments, drug treatment was performed 24 hours pre-infection and 48 hours post-infection. C: Shows the effect of tryptophan and its metabolic intermediates on chlamydia infection. The symbols A to G on the horizontal axis correspond to the symbols on the right shoulder of the metabolite in FIG. 1A (A = L-tryptophan, B = 5-hydroxytryptophan, C = kynurenine, D = serotonin, E = melatinin, respectively. , F = 5-hydroxytryptophanol, G = 5-methoxyindole acid acid), the numbers are C.I. for human HEp-2 cells. It represents the concentration (50,200 μM) of each substance at the time of infection experiment of Pneumoniae J138 strain. None of A to G showed toxicity to host cells under the conditions of this experiment. The vertical axis of the graph shows the relative value of the infection rate with respect to the control (no treatment) (control = 100), the graph shows the average value in three repeated experiments, and the attached bar shows ± 1SD. Those with a significant difference from the control were marked with * (t test, p <0.01). The effects of melatonin and interferon-γ (IFN-γ) on Chlamydia infection were compared. A: Shows the effect of each substance on Chlamydia infection. + And − represent the presence or absence of melatonin (100 μM), IFN-γ (1.0 ng / ml) and tryptophan (200 μg / ml), respectively. The vertical axis is the relative value of the infection rate relative to the control (left end, 100), each graph shows the average value of three repeated experiments, and the attached bar shows ± 1 SD. B: Inclusion bodies in Chlamydia infection were visualized with FITC-labeled Chlamydia specific antibodies (white squares in Inclusion body row). Each bar in the lower right of the photo is 10 μm. C: Size distribution (radius, horizontal axis) of inclusion bodies in each of melatonin treatment, IFN-γ treatment, and control. The comparison of melatonin sensitivity by Chlamydia species is shown. C. pneumoniae, C.I. felis, C.I. Each trachomatis was treated with melatonin at 25 μM, 50 μM, and 100 μM, and compared with IFN-γ treatment. The vertical axis of the graph indicates the relative infection rate (control = 100), and the horizontal axis indicates the presence or absence of treatment. C. to HE-p2 cells. We searched for melatonin and serotonin targets in pneumoniae infection. A: HE-p2 cells, C.I. Each of pneumoniae J138 strain was treated with melatonin / serotonin alone, and the influence on subsequent infection was examined. Chlamydia cells were treated at the concentration of 200 μM in the same solution as the HEp-2 cell culture solution 90 minutes before infection. * Indicates that there was a significant difference between control and treatment (Student t test, p <0.05). B: Pertussis toxin (pertussis toxin, 20 ng / ml), which is a G protein inhibitor, was added to each of melatonin treatment and seratonin treatment for 48 hours, and the effect was examined. The schematic diagram of the tryptophan synthesis pathway in Chlamydia bacteria and a host cell is shown. As genes involved in tryptophan biosynthesis in Chlamydia bacteria, kynU, kprS, trpD, trpF, trpC, trpF, trpC, trpA, trpB work at each stage of the synthetic pathway. C. Infecting cats Felis has all of these gene sets, but C. infects humans. trachomatis has only an incomplete gene set. no pneumoniae. It is known that administration of interferon-γ against Chlamydia bacteria causes tryptophan deficiency in the kynurenine pathway and causes chlamydia inhibition.

Claims (15)

  A composition characterized by suppressing infection or growth of Chlamydia bacteria, comprising a tryptophan metabolite as an active ingredient.   A pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the tryptophan metabolic intermediate product is 5-hydroxytryptophan, melatonin, serotonin and these A pharmaceutical composition characterized in that it is selected from at least one of a pharmacologically acceptable salt, ester or derivative.   A pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the tryptophan metabolic intermediate product is any of 5-hydroxytryptophan, melatonin, and serotonin Pharmaceutical composition characterized by being chosen from these.   A pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the tryptophan metabolic intermediate product is at least one of 5-hydroxytryptophan, serotonin, and melatonin A pharmaceutical composition characterized in that it is selected from one and the effective concentration of the inhibition is in the range of 2 to 10 times the concentration in the body.   A pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the tryptophan metabolic intermediate product is at least one of 5-hydroxytryptophan, serotonin, and melatonin A pharmaceutical composition characterized in that it is selected from one and the effective concentration of said inhibition is in the range of 5 μM to 500 μM.   A pharmaceutical composition characterized by suppressing infection or growth of Chlamydia bacteria, comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the tryptophan metabolic intermediate product is at least one of 5-hydroxytryptophan, serotonin, and melatonin The effective concentration of the inhibition is within the range of 50 μM to 500 μM for 5-hydroxytryptophan, within the range of 50 μM to 100 μM for serotonin, and within the range of 5 μM to 500 μM for melatonin. A pharmaceutical composition, characterized in that it is.   A pharmaceutical composition characterized by suppressing infection or proliferation of Chlamydia bacteria, comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the Chlamydia bacteria are Chlamydia trachomatis, Chlamydia pneumoniae, Chlamydia citasi A pharmaceutical composition characterized by being at least one of Chlamydia ferris.   A pharmaceutical composition characterized by suppressing infection or proliferation of Chlamydia bacteria, comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the Chlamydia bacteria are Chlamydia trachomatis, Chlamydia pneumoniae, Chlamydia citasi The pharmaceutical composition according to any one of claims 2 to 6, wherein the composition is at least one of Chlamydia ferris.   A pharmaceutical composition characterized by suppressing infection or growth of Chlamydia spp., Comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the drug is any one of an oral drug, a coating drug, an eye drop, and an injection. A pharmaceutical composition characterized in that it is selected from the following.   A pharmaceutical composition characterized by suppressing infection or growth of Chlamydia spp., Comprising a tryptophan metabolic intermediate product as an active ingredient, wherein the drug is any one of an oral drug, a coating drug, an eye drop, and an injection. The pharmaceutical composition according to any one of claims 2 to 8, wherein the pharmaceutical composition is selected from the following.   A food composition characterized by suppressing infection or growth of Chlamydia spp., Comprising a tryptophan metabolite as an active ingredient.   A food composition characterized by suppressing infection or growth of Chlamydia bacteria, comprising a tryptophan metabolite as an active ingredient, wherein the tryptophan metabolite is 5-hydroxytryptophan, serotonin, melatonin, and these A food composition characterized by being selected from at least one of a pharmacologically acceptable salt, ester or derivative.   A food composition characterized by suppressing infection or proliferation of Chlamydia spp., Comprising a tryptophan metabolite as an active ingredient, wherein the tryptophan metabolite is at least one of 5-hydroxytryptophan, serotonin, and melatonin A food composition characterized by being selected from one.   A food composition characterized by suppressing infection or proliferation of Chlamydia spp., Comprising a tryptophan metabolite as an active ingredient, wherein the tryptophan metabolite is at least one of 5-hydroxytryptophan, serotonin, and melatonin A food composition, characterized in that it is selected from one of the above, and the food is one of a candy, a gum and a soft drink.   15. A food comprising the food composition according to any one of claims 11 to 14, which suppresses infection or proliferation of Chlamydia bacteria.

Images